TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (NCT02693535)
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama
Age range: 12 Years
🧪 Interventions in This Study
- Palbociclib (DRUG)
- Sunitinib (DRUG)
- Temsirolimus (DRUG)
- Trastuzumab and Pertuzumab (DRUG)
- Vemurafenib and Cobimetinib (DRUG)
- Regorafenib (DRUG)
- Olaparib (DRUG)
- Nivolumab and Ipilimumab (DRUG)
- Abemaciclib (DRUG)
- Talazoparib (DRUG)
- Atezolizumab and Talazoparib (DRUG)
- Tucatinib plus Trastuzumab Subcutaneous (SC) (DRUG)
- Futibatinib (DRUG)
- Dabrafenib plus Trametinib (DRUG)
- Fam-Trastuzumab Deruxtecan-Nxki (TDxD) (DRUG)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (181 Sites)
Showing the first 25 of 181 sites.
- University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama
- Cancer Treatment Centers of America-Phoenix — Phoenix, Arizona
- Sutter Auburn — Auburn, California
- Sutter Alta Bates — Berkeley, California
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate — Los Angeles, California
- Kaiser Permanente - Oakland Medical Center — Oakland, California
- Sutter Palo Alto Medical Foundation: Palo Alto — Palo Alto, California
- Kaiser Permanente - Roseville Medical Center — Roseville, California
- Sutter Roseville — Roseville, California
- Kaiser Permanente - Sacramento Medical Center — Sacramento, California
- Sutter Sacramento — Sacramento, California
- Kaiser Permanente - South San Francisco Medical Center — San Francisco, California
- California Pacific Medical Center Research Institute — San Francisco, California
- Kaiser Permanente - San Francisco Medical Center — San Francisco, California
- Sutter Cancer Research Consortium — San Francisco, California
- Kaiser Permanente - San Jose Medical Center — San Jose, California
- Kaiser Permanente - San Leandro Medical Center — San Leandro, California
- Sutter Sansum Clinic — Santa Barbara, California
- Kaiser Permanente - Santa Clara Medical Center — Santa Clara, California
- Sutter Palo Alto Medical Foundation: Santa Cruz — Santa Cruz, California
- Sutter Palo Alto Medical Foundation: Fremont — Santa Cruz, California
- Sutter Palo Alto Medical Foundation: Sunnyvale — Sunnyvale, California
- Kaiser Permanente - Vallejo Medical Center — Vallejo, California
- Kaiser Permanente - Walnut Creek Medical Center — Walnut Creek, California
- Saint Vincent's Medical Center (SVMC) — Bridgeport, Connecticut
📞 Contact the Study Coordinator
Phone: (205) 644-2584
Email: kunyuan@uabmc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma, Non-Hodgkin
- NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers — Denver, Colorado
- A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) — Duarte, California
- A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) — Santa Monica, California
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma — Duarte, California
- Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma — St Louis, Missouri
- A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma — Pasadena, California
Explore by condition: All Lymphoma, Non-Hodgkin clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.